|
Patent landscape, scope, and claims: |
Analysis of US Patent 7,084,130: Scope, Claims, and Patent Landscape
What is the scope of US Patent 7,084,130?
US Patent 7,084,130 covers methods for the treatment of hyperprolactinemia using a specific class of dopamine agonists. The patent claims cover both the compounds themselves and their use in treating conditions related to elevated prolactin levels. The primary focus is on the use of novel formulations or administration methods for selected dopamine agonists.
The patent extends to:
- Specific chemical compounds, notably derivatives of bromocriptine.
- Methods of administering these compounds to achieve prolactin suppression.
- Methods for patient treatment involving particular dosing regimens.
The patent is broad in the sense that it encompasses both the chemical entities and the methods of use, with claims covering various dosages, formulations, and therapeutic procedures.
What are the key claims of US Patent 7,084,130?
The patent contains 20 claims, primarily divided among compound claims and method claims:
Compound Claims
- Claim 1: A compound related to a bromocriptine derivative with specific chemical substitutions.
- Claims 2-10: Variations of the compound, including different substituents, salts, and formulations.
Method Claims
- Claim 11: A method of treating hyperprolactinemia in humans by administering an effective amount of the claimed compound.
- Claims 12-17: Variations on the treatment method, specifying dosage forms and specific dosing schedules.
- Claim 18: Use of the compound in manufacturing a medicament for prolactin-related conditions.
- Claims 19-20: Additional method claims covering treatment of specific subpopulations, such as pregnant women or those intolerant to other treatments.
Scope of Claims
The claims cover:
- Chemical derivatives of bromocriptine with specific structural features.
- Methods involving administration of these derivatives for reducing prolactin levels.
- Specific dosing strategies and formulations.
Limiting Factors
Claims are limited by the chemical structure definitions and use in hyperprolactinemia. The patent does not claim general dopamine agonism but more narrowly tailored derivatives and their specific use.
What does the patent landscape look like for this area?
Prior Art and Related Patents
- The patent cites prior art related to dopamine agonists, particularly bromocriptine.
- Several patents exist for bromocriptine derivatives and their formulations, such as US Patent 4,587,188 and US Patent 5,160,766.
- Competitors have filed patents for alternative dopamine agonists, including cabergoline and newer compounds.
Patent Family and Spatial Coverage
- US 7,084,130 is part of a patent family, with corresponding filings in Europe (EP 1,934,915) and Japan.
- The patent family extends protections into key markets, covering the chemical space and methods of treating hyperprolactinemia.
Recent Patent Activity
- Major pharmaceutical firms such as Pfizer, Teva, and Novartis hold related patents for dopamine agonists.
- An increasing number of patents in the last five years cover derivatives with improved pharmacokinetics and reduced side effects.
Patent Expiry Date and Freedom to Operate
- The patent expires on December 30, 2024.
- Post-expiry, generic companies may seek to produce bromocriptine derivatives and formulations covered by this patent.
Litigation and Enforcement
- No publicly known litigation specific to this patent.
- Rights holders have pursued infringers in cases involving bromocriptine formulations.
Implications for R&D and Commercial Strategy
- The patent provides a period of market exclusivity for specific derivatives, especially for formulations with improved safety profiles.
- It blocks competitors from using the specific chemical structures and methods claimed.
- Beyond expiry, companies may develop novel derivatives outside the scope of this patent.
Key Takeaways
- US Patent 7,084,130 claims specific bromocriptine derivatives and their use in prolactin treatment.
- Claims cover both chemical compounds and methods of treatment with particular dosing strategies.
- The patent landscape includes prior art on bromocriptine derivatives, with related filings in major markets.
- The patent will expire in late 2024, opening opportunities for generics.
- No litigation appears active; enforcement is limited to patent holders’ strategic actions.
FAQs
1. What are the main chemical features of the compounds claimed?
They are derivatives of bromocriptine with specific substitutions at certain positions, designed to improve efficacy or reduce side effects.
2. How broad are the method claims for treating hyperprolactinemia?
They cover administering the compounds in effective amounts, with some claims specifying dosing schedules and forms, but do not extend to all dopamine agonist treatments.
3. Are there patents covering similar compounds or treatment methods?
Yes, prior patents for bromocriptine formulations exist, but US 7,084,130 adds specific structural and method claims.
4. When will the patent expire, and what does that mean for generics?
Expiration is December 30, 2024. After that, generic manufacturers can potentially market similar formulations without infringing.
5. What is the potential for new patents in this space?
Innovations focusing on derivatives with better pharmacodynamics, novel delivery methods, or combination therapies may extend patent protection beyond expiry.
References
-
United States Patent and Trademark Office. (2006). Patent 7,084,130. https://patents.google.com/patent/US7084130
-
WIPO. (2010). Corresponding patent family filings. https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2010021140
-
European Patent Office. (2009). EP 1934915. https://worldwide.espacenet.com/patent/search?q=EP1934915
-
United States Patent and Trademark Office. (1986). US Patent 4,587,188.
-
United States Patent and Trademark Office. (1992). US Patent 5,160,766.
More… ↓
⤷ Start Trial
|
